HomeInvestors & MediaNews
ABL Bio Enters Global Collaboration and License Agreement with SANOFI to Advance ABL301 for ...
- ABL and SANOFI to collaborate on the development of ABL301, a potential first-in-class bispecific antibody targeting alpha-synuclein and containing a proprietary brain shuttle, for alpha-synucleinopathies, including Parkinson’s disease- ABL301 uses ABL’s Grabody-B platform technology to effectively cross the blood-brain barrier- ABL to receive $75M upfront and up to $985M in potential milestone payments for exclusive global license to ABL301 January 11, 2022, SEONGNAM, South Korea - ABL Bio, Inc. (KOSDAQ: 298380), a clinical-stage biotech developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, today announced an exclusive collaboration and worldwide license agreement with SANOFI to develop and commercialize ABL301, a pre-clinical stage bispecific antibody targeting alpha-synuclein and IGF1R to treat Parkinson’s disease and other potential indications with enhanced blood-brain barrier (BBB) penetration. Under the terms of the agreement, ABL will receive $75 million in upfront payments. In addition, ABL is eligible to receive up to $985 million based on the achievement of predefined development, regulatory and commercialization milestones, including $45 million in near-term milestones. ABL is also eligible to receive royalties on net sales if the product from the collaboration is commercialized. The transaction will become effective after customary closing conditions are met, such as the HSR clearance. SANOFI will receive worldwide exclusive development and commercialization rights to ABL301. Meanwhile, ABL will lead the preclinical development and Phase 1 clinical trial of ABL301. Thereafter, SANOFI will be responsible for further clinical development, regulatory approval and commercialization of ABL301 worldwide. Grabody-B is a BBB shuttling platform that targets the insulin-like growth factor 1 receptor (IGF1R) to maximize BBB penetration of potential therapies for various CNS-related diseases. Utilizing Grabody-B technology, ABL301 effectively carries the anti-alpha-synuclein antibody across the BBB to enhance therapeutic efficacy against Parkinson’s disease. “This groundbreaking partnership with SANOFI proves the immense possibilities of ABL’s innovative bispecific antibody technology” said Sang Hoon Lee, PhD, CEO of ABL Bio. “We will continue to develop our Grabody-B platform and expand its applicability in other neurodegenerative diseases, such as Alzheimer’s, to contribute to improving the lives of patients worldwide.” About ABL301ABL301 is a bispecific antibody composed of an anti-alpha-synuclein antibody and Grabody-B, a BBB-penetrating shuttle targeting insulin-like growth factor 1 receptor (IGF1R). It is being developed as a potential first-in-class bispecific antibody therapeutics for the treatment of synucleinopathies, including Parkinson’s disease. In preclinical studies, ABL301’s anti-alpha-synuclein domain showed robust recognition of pathological aggregates with high affinity and with minimal affinity to monomeric alpha-synuclein. By utilizing the Grabody-B platform, ABL301 is proven to enter the brains and cerebrospinal fluid (CSF) of rodents and non-human primates more efficiently than an alpha-synuclein monoclonal antibody. Due to its superior BBB-penetrating capability, ABL301 showed better efficacy to reduce brain aggregated alpha-synuclein in a Parkinson’s disease mouse model than the monoclonal alpha- synuclein binding antibody. About Grabody-BLow brain exposure has been one of the major obstacles to the development of central nervous system (CNS) drugs. Grabody-B is a molecular shuttle to facilitate the CNS-penetration of therapeutics through straightforward generation of a bispecific antibody or antibody-drug conjugate. Grabody-B is a non-neutralizing anti-IGF1R antibody and therefore does not interfere with IGF1R signaling nor seriously affect the body’s innate IGF1R axis. Grabody-B has proven to induce significantly higher BBB-penetration of various therapeutic antibodies in rodents and non-human primates with superior efficacy or pharmacodynamic effects compared to monoclonal antibodies. Given IGF1R’s relatively specific expression in the CNS and its non-neutralizing property, Grabody-B is believed to be a safe and efficient shuttle to enhance the efficacy of therapeutics for various CNS-related diseases in clinics. About ABL BioABL Bio, Inc. (KOSDAQ: 298380) is a clinical-stage biotechnology company developing antibody therapeutics for immune-oncology and neurodegenerative diseases. With internal R&D and global partnerships, ABL has developed multiple BsAb platforms, such as ‘Grabody-T,’ ‘Grabody-I’ and ‘Grabody-B’ and built an innovative pipeline of multiple clinical and pre-clinical stage drug candidates. In the oncology area, we have developed Grabody-T, a modular 4-1BB engaging platform that has demonstrated superior efficacy and safety. In the neurodegenerative disorder space, we have developed Grabody-B, which is designed to maximize blood-brain barrier (BBB) penetration. Grabody-B is applicable to various CNS targets across a plethora of neurological disorders, potentially providing a breakthrough to address the high unmet medical needs in neurodegeneration. For more information, please visit www.ablbio.com
2022-01-12ablbio
ABL Bio to Present ABL602 Data at the 63rd ASH Annual Meeting
- ABL602 is a CLL-1/CD3 bispecific antibody for acute myeloid leukemia- Preclinical data highlight potential of ABL602 as a new treatment for AML November 5, 2021, SEONGNAM - ABL Bio, Inc. (KOSDAQ: 298380), a clinical-stage biotech developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, today announced that new preclinical data for its ABL602, a T-cell engager bispecific antibody targeting CLL-1 and CD3 to treat acute myeloid leukemia (AML), will be presented at the 63rd American Society of Hematology (ASH) Annual Meeting, taking place both online and offline from December 11-14, 2021. “As part of our aim to apply our innovative bispecific antibody technology to a wide range of indications, we are striving to expand our portfolio of blood cancer therapeutics,” said Sang Hoon Lee, PhD, CEO of ABL Bio. “We look forward to participating in the 2021 ASH annual meeting, which will be the first time we showcase ABL602 to a global audience.” Details of the accepted abstract are as follows: Title: A Novel Asymmetrical Anti-CLL-1 x CD3 Bispecific Antibody, ABL602, Induces Potent CLL1-Specific Antitumor Activity with Minimized Sensitization of Pro-Inflammatory CytokinesAbstract Number: 145274Session Title: Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster IIDate & Time: 6:00 PM – 8:00 PM, Sunday, December 12, 2021 About ABL BioABL Bio, Inc. (KOSDAQ: 298380) is a clinical-stage biotechnology company developing antibody therapeutics for immune-oncology and neurodegenerative diseases. With internal R&D and global partnerships, ABL has developed multiple BsAb platforms, such as ‘Grabody-T,’ ‘Grabody-I’ and ‘Grabody-B’ and built an innovative pipeline of multiple clinical and pre-clinical stage drug candidates. In the oncology area, we have developed Grabody-T, a modular 4-1BB engaging platform that has demonstrated superior efficacy and safety. In the neurodegenerative disorder space, we have developed Grabody-B, which is designed to maximize blood-brain barrier(BBB) penetration. Grabody-B is applicable to various CNS targets across a plethora of neurological disorders, potentially providing a breakthrough to address the high unmet medical needs in neurodegeneration. For more information, please visit www.ablbio.com ABL ContactsInvestor InquiriesHyunjun Kiminvestor.relations@ablbio.com+82 31 8018 9845Media InquiriesHee Jun Parkmedia.relations@ablbio.com+82 31 8014 7032
2021-11-05ablbio
[Korea Times] ABL Bio leading Korea's new drug development
https://www.koreatimes.co.kr/www/tech/2021/09/693_316203.html?RD
2021-09-29ablbio
ABL Bio Receives IND Approval for Phase 1 Clinical Trial of ABL501, an anti-LAG-3/PD-L1 Bisp...
- South Korea’s MFDS clears IND application for a Phase 1 study evaluating the safety and preliminary efficacy of ABL501 as a monotherapy for solid tumor treatment- ABL’s third IND this year for bispecific antibody therapeutics August 4, 2021, SEONGNAM, South Korea - ABL Bio, Inc. (KOSDAQ: 298380), a clinical-stage biotech developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, today announced that the Investigational New Drug (IND) application for ABL501 has been approved by South Korea’s Ministry of Food and Drug Safety (MFDS). The Phase 1 clinical trial is an open-label, multi-center dose escalation and dose expansion study designed to evaluate the safety, tolerability, maximum tolerated dose (MTD) and preliminary efficacy of ABL501 in patients with advanced or metastatic solid tumors. ABL501 uses Grabody-I platform technology to simultaneously block PD-L1 and LAG-3-mediated T cell inhibition. Preclinical results demonstrate a synergistic increase of T cell activation that is higher than the enhancements induced by combination of anti-PD-L1 and LAG-3. ABL501 also showed a good safety profile in monkeys. “LAG-3 is emerging as a promising target for cancer immunotherapy. We look forward to verifying ABL501’s potential as a best-in-class bispecific antibody that overcomes the limitations of current LAG-3 targeting antibodies,” said Sang Hoon Lee, Ph.D., CEO of ABL Bio. “This is already our third IND approval this year, demonstrating our strong commitment to building a robust portfolio of bispecific antibody immunotherapies. Carrying on this momentum, we expect to submit multiple additional INDs next year.” About ABL BioABL Bio, Inc. (KOSDAQ: 298380) is a clinical-stage biotechnology company developing antibody therapeutics for immune-oncology and neurodegenerative diseases. With internal R&D and global partnerships, ABL has developed multiple BsAb platforms, such as ‘Grabody-T,’ ‘Grabody-I’ and ‘Grabody-B’ and built an innovative pipeline of multiple clinical and pre-clinical stage drug candidates. In the oncology area, we have developed Grabody-T, a modular 4-1BB engaging platform that has demonstrated superior efficacy and safety. In the neurodegenerative disorder space, we have developed Grabody-B, which is designed to maximize blood-brain barrier(BBB) penetration. Grabody-B is applicable to various CNS targets across a plethora of neurological disorders, potentially providing a breakthrough to address the high unmet medical needs in neurodegeneration. For more information, please visit www.ablbio.com ABL ContactsInvestor InquiriesHyunjun Kiminvestor.relations@ablbio.com+82 31 8018 9845 Media InquiriesHee Jun Parkmedia.relations@ablbio.com+82 31 8014 7032
2021-08-04ablbio
ABL Bio Announces Publication of Preclinical Data Demonstrating Safety and Efficacy of ABL50...
- ABL503/TJ-L14B demonstrates stronger anti-tumor efficacy than anti-PD-L1 or anti-4-1BB monotherapy as well as a good safety profile- ABL503 currently in Phase 1 trial to evaluate the safety, tolerability, MTD PK and PD in patients with advanced or metastatic solid tumors July 9, 2021 - ABL Bio, Inc. (KOSDAQ: 298380), a clinical-stage biotech developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, today announced the publication of pre-clinical data highlighting the safety and anti-tumor efficacy of ABL503/TJ-L14B in the Journal for ImmunoTherapy of Cancer(JITC). Jointly developed with I-Mab (NASDAQ: IMAB), ABL503 is a bispecific antibody combining PD-L1 checkpoint pathway with 4-1BB agonistic activity to overcome the current limitation of PD-(L)1 therapy and 4-1BB related toxicity. Using ABL’s Grabody-T bispecific antibody platform technology, ABL503 induces 4-1BB activation only in the presence of PD-L1 expressing tumors to minimize the risk of 4-1BB related peripheral toxicity. ABL503 is currently being evaluated in a Phase 1 study in the U.S. in patients with locally advanced or metastatic solid tumors (NCT04762641). The paper, “Novel anti-4-1BB X PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade,” was published in collaboration with Su-Hyung Park, PhD, Professor at the KAIST Graduate School of Medical Science and Engineering. The paper highlights key in vitro and in vivo research that demonstrate ABL503’s potential as a promising immunotherapeutic agent against cancer. In the study, ABL503 induced complete tumor regression in humanized mice, which was superior to anti-PD-L1 or anti-4-1BB monotherapy. Moreover, no tumor growth was observed in these mice when they were rechallenged at 40 days after their first ABL503 treatment, demonstrating that ABL503 treatment yields a prolonged anti-tumor response despite a short-term administration schedule. In addition, ABL503 was well-tolerated following a repeated high dose administration of ABL503 in monkeys. Monkeys treated with ABL503 exhibited overall good tolerance with normal liver functions. “These published data validate our Grabody-T platform technology to achieve anti-tumor efficacy with a low risk of off-tumor liver toxicity and support the therapeutic value of ABL503 as a potential best-in-class treatment for cancer,” said Sang Hoon Lee, Ph.D., CEO of ABL Bio. “We have great expectations for the program and look forward to further evaluating ABL503 in our Phase 1 study with I-Mab.” About ABL Bio ABL Bio, Inc. (KOSDAQ: 298380) is a clinical-stage biotechnology company developing antibody therapeutics for immune-oncology and neurodegenerative diseases. With internal R&D and global partnerships, ABL has developed multiple BsAb platforms, such as ‘Grabody-T,’ ‘Grabody-I’ and ‘Grabody-B’ and built an innovative pipeline of multiple clinical and pre-clinical stage drug candidates. In the oncology area, we have developed Grabody-T, a modular 4-1BB engaging platform that has demonstrated superior efficacy and safety. In the neurodegenerative disorder space, we have developed Grabody-B, which is designed to maximize blood-brain barrier (BBB) penetration. Grabody-B is applicable to various CNS targets across a plethora of neurological disorders, potentially providing a breakthrough to address the high unmet medical needs in neurodegeneration. For more information, please visit www.ablbio.com ABL ContactsInvestor InquiriesHyunjun Kiminvestor.relations@ablbio.com+82 31 8018 9845 Media InquiriesHee Jun Parkmedia.relations@ablbio.com+82 31 8014 7032
2021-07-09ablbio
ABL Bio Announces the Publication of Paper Reviewing Bispecific Antibody-Based Cancer Immuno...
- Review paper describing the development status of bispecific antibodies published in Vaccines- ABL Bio to continue to expand its ‘Grabody’ bispecific antibody platform to bring effective immunotherapy options to patients July 5, 2021 - ABL Bio, Inc. (KOSDAQ: 298380), a clinical-stage biotech developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, today announced the publication of a peer-reviewed review paper in Vaccines highlighting the potential of bispecific antibodies as the next generation cancer treatment. Co-authored by Professor Seung-Woo Lee of the Department of Life Sciences at POSTECH and his team, the paper is titled “Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies.” In the review, bispecific antibodies are classified into four categories: immune effector cell redirectors, tumor-targeted immunomodulators, dual immunomodulators, and dual tumor-targeting BsAbs. The paper provides an overview of each of these immunotherapies in clinical development as well as strategies to help overcome limitations. “We are delighted to see our review paper published in Vaccines in collaboration with ABL Bio, a company pioneering research and development efforts in the field of bispecific antibodies,” said Professor Seung-Woo Lee. “We expect this paper to provide key insights into the current status of the development of bispecific antibodies, believed to be the next generation of immunotherapies for cancer patients.” ABL Bio has developed a set of innovative bispecific antibody platforms and pipelines. Among them, ABL503 (PD-L1 X 4-1BB) and ABL111 (Claudin18.2 X 4-1BB), bispecifics that utilize ‘Grabody-T’ platform technology are currently in Phase 1 clinical trials in the U.S. An investigational new drug (IND) application for ABL501 (LAG-3 X PD-L1) has also been submitted recently to the Ministry of Food and Drug Safety in South Korea. Multiple additional programs are expected to enter clinical trials next year. “The global market for bispecific antibodies is continuously expanding, reflected in the increasing number of new clinical studies and the recent licensing deals signed by global pharmaceutical companies,” said Sang Hoon Lee, Ph.D., CEO of ABL Bio. “We plan to continue to expand our Grabody platforms to build a more robust bispecific antibody portfolio that can offer safe and promising treatment options.” About ABL Bio ABL Bio, Inc. (KOSDAQ: 298380) is a clinical-stage biotechnology company developing antibody therapeutics for immuno-oncology and neurodegenerative diseases. With internal R&D and global partnerships, ABL has developed multiple BsAb platforms, such as ‘Grabody-T,’ ‘Grabody-I’ and ‘Grabody-B’ and built an innovative pipeline of multiple clinical and pre-clinical stage drug candidates. In the oncology area, we have developed Grabody-T, a modular 4-1BB engaging platform that has demonstrated superior efficacy and safety. In the neurodegenerative disorder space, we have developed Grabody-B, which is designed to maximize blood-brain barrier(BBB) penetration. Grabody-B is applicable to various CNS targets across a plethora of neurological disorders, potentially providing a breakthrough to address the high unmet medical needs in neurodegeneration. For more information, please visit www.ablbio.com
2021-07-05ablbio
ABL Bio to Present New Preclinical Data on 'Grabody-B' at BBB Summit
- Oral presentation on the mechanism and application of Grabody-B, an IGF1R-mediated BBB shuttle- ABL expects IND submission of ABL301, a Grabody-B-applied bispecific antibody targeting alpha-synuclein, in 2022 June 28, 2021 - ABL Bio, Inc. (KOSDAQ: 298380), a clinical-stage biopharmaceutical company developing bispecific antibody platforms for immuno-oncology and neurodegenerative diseases, today announced it will share new preclinical data on its ‘Grabody-B’ platform at the 3rd Annual Blood-Brain Barrier Summit, held online June 28-30, 2021. Grabody-B is a bispecific antibody platform that targets the human insulin like-growth factor receptor (IGF1R), primarily expressed in brain endothelial cells, to maximize BBB penetration of antibodies. Its lead molecule, ABL301, a bispecific antibody targeting alpha synuclein to treat Parkinson’s disease, showed 13-fold higher brain penetration compared to an anti α-syn monoclonal antibody in non-human primates. Its PK analysis also showed sustained penetration over time with good safety profiles. “Grabody-B is gaining recognition as a next-generation BBB shuttle platform that is distinguished from other platforms that target the transferrin receptor,” said Sang Hoon Lee, PhD, CEO of ABL Bio. “With growing interest in BBB-penetrating technology following the FDA’s approval of Biogen’s aducanumab, we expect to exchange productive interactions on current trends regarding the global CNS drug market and research and development.” Highlights of the presentation include: - Various therapeutic antibodies fused with Grabody-B showed higher CNS exposure than monoclonal antibodies in both rodents and non-human primates, proving Grabody-B’s versatile applicability- The relation between the improved CNS exposure and pharmacodynamic effect was well-established in both rodents and non-human primates- ABL301 showed better efficacy than anti-a-syn monoclonal Ab in both Parkinson’s Disease and MSA models About ABL Bio ABL Bio, Inc. (KOSDAQ: 298380) is a clinical-stage biotechnology company developing antibody therapeutics for immuno-oncology and neurodegenerative diseases. With internal R&D and global partnerships, ABL has developed multiple BsAb platforms, such as ‘Grabody-T,’ ‘Grabody-I’ and ‘Grabody-B’ and built an innovative pipeline of multiple clinical and pre-clinical stage drug candidates. In the oncology area, we have developed Grabody-T, a modular 4-1BB engaging platform that has demonstrated superior efficacy and safety. In the neurodegenerative disorder space, we have developed Grabody-B, which is designed to maximize blood-brain barrier(BBB) penetration. Grabody-B is applicable to various CNS targets across a plethora of neurological disorders, potentially providing a breakthrough to address the high unmet medical needs in neurodegeneration. For more information, please visit www.ablbio.com
2021-06-28ablbio
ABL Bio Anticipates Acceleration of ABL001 Global Studies and Cancer Immunotherapy Pipeline ...
- TRIGR merges with U.S. clinical-stage biopharma Compass Therapeutics- ABL-TRIGR terminate 2018 licensing agreement, allowing ABL to accelerate independent development of bispecific antibody candidates for clinical development May 14, 2021 - ABL Bio, Inc., a South Korean biotech developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, said in a press release today that it expects the merger between its global partner TRIGR Therapeutics and Compass Therapeutics to help accelerate the global clinical development of its lead candidate ABL001(CTX-009/TR009/NOV1501). ABL001 is a bispecific antibody targeting VEGF and DLL4 to treat cancer patients with solid tumors, currently in a Phase 1b study being conducted in South Korea. Compass Therapeutics is a clinical-stage biopharmaceutical company based in Boston, focused on developing therapeutic antibodies that target the immune system to treat cancer or autoimmune diseases. Having received financing from leading healthcare investment firms, including OrbiMed and F-Prime Capital, Compass has developed a broad pipeline of monoclonal and multispecific therapeutic candidates, with its lead 4-1BB based molecule CTX-471 currently in Phase 1 clinical study in the U.S. The new entity possesses the global rights for ABL001, excluding the Republic of Korea and Greater China, through a licensing agreement signed by ABL and TRIGR in 2018. Compass plans to file an Investigational New Drug(IND) in the U.S. for ABL001 later this year, adding momentum to the global development of the drug. As part of the merger, ABL has agreed to terminate its 2018 licensing agreement that granted TRIGR the global rights(excluding the Republic of Korea) to five of its pre-clinical stage antibodies. This comes as Compass seeks to position itself as a clinical-stage company and avoid 4-1BB-targeting pipelines that may overlap with its own. This allows ABL to significantly enhance its cancer immunotherapy portfolio through its independent development of bispecific antibody candidates ABL101(BCMA X 4-1BB) and ABL103(B7-H4 X 4-1BB). ABL plans to proceed with IND filing early next year to initiate Phase 1 clinical trial of ABL101 and submit another IND application for ABL103 later the same year. About ABL Bio ABL Bio, Inc. (KOSDAQ: 298380) is a clinical-stage biotechnology company developing antibody therapeutics for immuno-oncology and neurodegenerative diseases. With internal R&D and global partnerships, ABL has developed multiple BsAb platforms, such as ‘Grabody-T,’ ‘Grabody-I’ and ‘Grabody-B’ and built an innovative pipeline of multiple clinical and pre-clinical stage drug candidates. In the oncology area, we have developed Grabody-T, a modular 4-1BB engaging platform that has demonstrated superior efficacy and safety. In the neurodegenerative disorder space, we have developed Grabody-B, which is designed to maximize blood-brain barrier(BBB) penetration. Grabody-B is applicable to various CNS targets across a plethora of neurological disorders, potentially providing a breakthrough to address the high unmet medical needs in neurodegeneration. For more information, please visit www.ablbio.com
2021-05-14ablbio
ABL Bio Announces Publication of Study Demonstrating N-terminal Selective Conjugation Increa...
- ABL Bio’s N-terminal selective conjugation method results in enhanced stability and lower toxicity while also inducing more efficacy- NTERM-ADC demonstrates high anti-tumor potency in rats April 28, 2021, SEONGNAM - ABL Bio, Inc., a South Korean biotech developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, today announced a publication in the peer-reviewed journal mAbs, that shows ADCs are more stable and less toxic when applied with N-terminal selective conjugation. The paper, titled: “N-terminal selective conjugation method widens the therapeutic window of antibody-drug conjugates by improving tolerability and stability” demonstrates that NTERM-conjugated ADCs overcome the limitations of narrow therapeutic windows. To support this, the authors synthesized three different ADCs using different methods, including N-terminal selective conjugation, setting trastuzumab as the evaluation standard. As highlighted in the paper, the NTERM ADC demonstrated a longer half-life than others in a single-dose PK study in rats. While the other ADCs exhibited shorter half-lives of 84.6 hours and 53.2 hours, the half-life of the NTERM-ADC was 118.3 hours. In addition, the NTERM-ADC showed positive data in a toxicity study performed in rats. To examine the tolerability of ADCs, female rats were injected with each ADC intravenously. No severe side effects were observed in the NTERM-ADC group, whereas other groups displayed severe liver toxicity and thrombocytopenia that resulted in lower survival rates. Furthermore, the results confirmed the NTERM-ADC’s excellent anti-tumor efficacy. In a rat-xenograft model, the NTERM-ADC group showed complete remission in 5 of 6 rats after a single dose of 2.5 mpk. Even at a lower dose of 1 mpk, it showed 92% of tumor growth inhibition from day 4 to 21. While a lower toxicity could mean a lower potency of the molecule, the NTERM-ADC demonstrated the best efficacy among the three groups in the xenograft model. ABL’s N-terminal selective conjugation method has been patented in the U.S., South Korea and Australia. Using this conjugation method, the company has developed ABL201, a bispecific antibody therapeutics candidate to treat rare blood cancer. The publication is available online in the journal website: https://bit.ly/3tYKgjN About ABL Bio ABL Bio, Inc. (Kosdaq: 298380) is a South Korean biotechnology company developing antibody therapeutics for immuno-oncology and neurodegenerative diseases. With internal R&D and global partnerships, ABL has developed multiple BsAb platforms, such as ‘Grabody-T,’ ‘Grabody-I’ and ‘Grabody-B’ and built an innovative pipeline of multiple clinical and pre-clinical stage drug candidates. In the oncology area, we have developed Grabody-T, a modular 4-1BB engaging platform that has demonstrated superior efficacy and safety. In the neurodegenerative disorder space, we have developed Grabody-B platform, which is designed to maximize blood-brain barrier (BBB) penetration. Grabody-B is applicable to various CNS targets across a plethora of neurological disorders, potentially providing a breakthrough to address the high unmet medical needs in neurodegeneration. For more information, please visit www.ablbio.com
2021-04-28전체관리자